Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business
By Sriparna Roy, Nandhini Srinivasan and Khushi Mandowara

U.S. FDA approves Travere Therapeutics kidney disorder drug

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

Travere Therapeutics said on Friday the U.S. health regulator has granted accelerated approval to its drug to treat a type of chronic kidney disease, IgAN, in adults with a high risk of advancing to kidney failure.

Shares of the drugmaker were up 2.8% at $18.32 after market

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.